{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:03:19Z","timestamp":1790996599711,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the long-term, real-life\u00a0effects on non-motor symptoms (NMS) of opicapone compared to entacapone in levodopa-treated people with Parkinson\u2019s disease (PwP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective data analysis, with pre- and post-opicapone initiation data of 17 PwP with motor fluctuations compared to a comparable group of 18 PwP introduced on entacapone. The primary outcome was changes in the NMS Scale (NMSS) total score after 1-year follow-up. Secondary outcomes included changes in the NMSS domains,\u00a0and Parkinson\u2019s Disease Sleep Scale (PDSS) total and item scores after the same time span.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Groups were comparable for baseline demographics and Parkinson\u2019s-related features (<jats:italic>p\u2009\u2265\u2009<\/jats:italic>0.314) as well as duration of follow-up (1.33\u2009\u00b1\u20090.66\u00a0years for PwP on opicapone and 1.23\u2009\u00b1\u20090.49\u00a0years for those on entacapone; <jats:italic>p\u2009=\u2009<\/jats:italic>0.858). PwP who were introduced on opicapone showed no changes in NMSS and PDSS total scores after 1 year (<jats:italic>p\u2009=\u2009<\/jats:italic>0.605 and <jats:italic>p\u2009=\u2009<\/jats:italic>0.507, respectively), whereas PwP who were introduced on entacapone showed significant worsening of NMSS and PDSS total scores at follow-up (<jats:italic>p\u2009=\u2009<\/jats:italic>0.005 and <jats:italic>p\u2009=\u2009<\/jats:italic>0.001, respectively). In neither group changes in individual NMSS domains from baseline to follow-up were observed (<jats:italic>p\u2009\u2265\u2009<\/jats:italic>0.288 for entacapone and <jats:italic>p\u2009\u2265\u2009<\/jats:italic>0.816 for opicapone, respectively). In PwP on entacapone significant worsening was seen in the distressing dreams, hallucinations, and limb numbness items of the PDSS (<jats:italic>p\u2009\u2264\u2009<\/jats:italic>0.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Introduction of opicapone in real-life PwP with motor fluctuations seems to stabilise NMS burden and aspects of sleep dysfunction, in contrast to entacapone where there was a worsening of NMS burden and PDSS scores over 1 year follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00702-023-02603-y","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T10:02:35Z","timestamp":1681120955000},"page":"925-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson\u2019s disease: opicapone versus entacapone"],"prefix":"10.1007","volume":"130","author":[{"given":"Valentina","family":"Leta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"van Wamelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Aureli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Metta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Cortelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Rodriguez-Blazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ray Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"issue":"5","key":"2603_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/s1474-4422(09)70068-7","volume":"8","author":"KR Chaudhuri","year":"2009","unstructured":"Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson\u2019s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464\u2013474. https:\/\/doi.org\/10.1016\/s1474-4422(09)70068-7","journal-title":"Lancet Neurol"},{"issue":"6","key":"2603_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/jnnp.73.6.629","volume":"73","author":"KR Chaudhuri","year":"2002","unstructured":"Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, Pezzela FR, Forbes A, Hogl B, Trenkwalder C (2002) The Parkinson\u2019s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 73(6):629\u2013635. https:\/\/doi.org\/10.1136\/jnnp.73.6.629","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2603_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/mds.27862","volume":"35","author":"KR Chaudhuri","year":"2020","unstructured":"Chaudhuri KR, Schrag A, Weintraub D, Rizos A, Rodriguez-Blazquez C, Mamikonyan E, Martinez-Martin P (2020) The movement disorder society nonmotor rating scale: initial validation study. Mov Disord 35(1):116\u2013133. https:\/\/doi.org\/10.1002\/mds.27862","journal-title":"Mov Disord"},{"issue":"1","key":"2603_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-022-02602-8","volume":"22","author":"KR Chaudhuri","year":"2022","unstructured":"Chaudhuri KR, Odin P, Ferreira JJ, Antonini A, Rascol O, Kurtis MM, Storch A, Bannister K, Soares-da-Silva P, Costa R, Magalh\u00e3es D, Rocha JF (2022) Opicapone versus placebo in the treatment of Parkinson\u2019s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (opicapone effect on motor fluctuations and pain) trial. BMC Neurol 22(1):88. https:\/\/doi.org\/10.1186\/s12883-022-02602-8","journal-title":"BMC Neurol"},{"key":"2603_CR5","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/j.parkreldis.2020.06.210","volume":"79","author":"R Hauser","year":"2020","unstructured":"Hauser R, Lew M, Comella C, Poewe W, Rascol O, Ferreira J, Olson K, Farahmand K, Shah C, Rocha J-F (2020) Night-time and morning OFF improvements with opicapone in patients with Parkinson\u2019s Disease and motor fluctuations: BIPARK-1 and BIPARK-2 pooled subanalyses. Parkinsonism Relat Disord 79:e53\u2013e54","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"2603_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha J-F, McCrory M, Soares-da-Silva P, Investigators B-S (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):197\u2013206","journal-title":"JAMA Neurol"},{"issue":"4","key":"2603_CR7","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3233\/jpd-202022","volume":"10","author":"V Leta","year":"2020","unstructured":"Leta V, van Wamelen DJ, Sauerbier A, Jones S, Parry M, Rizos A, Chaudhuri KR (2020) Opicapone and levodopa-carbidopa intestinal gel infusion: the way forward towards cost savings for healthcare systems? J Parkinsons Dis 10(4):1535\u20131539. https:\/\/doi.org\/10.3233\/jpd-202022","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"2603_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1756285613512392","volume":"7","author":"T M\u00fcller","year":"2014","unstructured":"M\u00fcller T (2014) Tolcapone addition improves Parkinson\u2019s disease associated nonmotor symptoms. Ther Adv Neurol Disord 7(2):77\u201382. https:\/\/doi.org\/10.1177\/1756285613512392","journal-title":"Ther Adv Neurol Disord"},{"key":"2603_CR9","first-page":"191","volume":"22","author":"CLAJ OliveiraFerreira","year":"2015","unstructured":"OliveiraFerreira CLAJ, Lopes N, Costa R, Pinto R et al (2015) Evaluation of non-motor symptoms in opicapone treated Parkinson\u2019s disease patients: results from a double-blind, randomized, placebo-controlled study and open-label extension. Eur J Neurol 22:191","journal-title":"Eur J Neurol"},{"issue":"3","key":"2603_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.14802\/jmd.20055","volume":"13","author":"KW Park","year":"2020","unstructured":"Park KW, Jo S, Lee SH, Hwang YS, Lee D, Ryu HS, Chung SJ (2020) Therapeutic effect of levodopa\/carbidopa\/entacapone on sleep disturbance in patients with Parkinson\u2019s Disease. J Mov Disord 13(3):205\u2013212. https:\/\/doi.org\/10.14802\/jmd.20055","journal-title":"J Mov Disord"},{"issue":"1","key":"2603_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-019-0179-3","volume":"9","author":"H Reichmann","year":"2020","unstructured":"Reichmann H, Lees A, Rocha J-F, Magalh\u00e3es D, Soares-da-Silva P (2020) Effectiveness and safety of opicapone in Parkinson\u2019s disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener 9(1):1\u20139","journal-title":"Transl Neurodegener"},{"key":"2603_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12030383","author":"D Santos Garc\u00eda","year":"2022","unstructured":"Santos Garc\u00eda D, Fern\u00e1ndez Pajar\u00edn G, Oropesa-Ruiz JM, Escamilla Sevilla F, Rahim L\u00f3pez RRA, Mu\u00f1oz Enr\u00edquez JG (2022) Opicapone improves global non-motor symptoms burden in Parkinson\u2019s disease: an open-label prospective study. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci12030383","journal-title":"Brain Sci"},{"issue":"2","key":"2603_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/nmt-2021-0057","volume":"12","author":"C Schofield","year":"2022","unstructured":"Schofield C, Chaudhuri KR, Carroll C, Sharma JC, Pavese N, Evans J, Foltynie T, Reichmann H, Zurowska L, Soares-da-Silva P, Lees A (2022) Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson\u2019s disease. Neurodegener Dis Manag 12(2):77\u201391. https:\/\/doi.org\/10.2217\/nmt-2021-0057","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"2603_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40263-020-00778-6","volume":"35","author":"LJ Scott","year":"2021","unstructured":"Scott LJ (2021) Opicapone: a review in Parkinson\u2019s disease. CNS Drugs 35(1):121\u2013131. https:\/\/doi.org\/10.1007\/s40263-020-00778-6","journal-title":"CNS Drugs"},{"issue":"1","key":"2603_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ane.13336","volume":"143","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen DJ, Martinez-Martin P, Weintraub D, Schrag A, Antonini A, Falup-Pecurariu C, Odin P, Ray Chaudhuri K (2021a) The non-motor symptoms scale in Parkinson\u2019s disease: validation and use. Acta Neurol Scand 143(1):3\u201312. https:\/\/doi.org\/10.1111\/ane.13336","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"2603_CR16","doi-asserted-by":"publisher","first-page":"9611","DOI":"10.1038\/s41598-021-88651-4","volume":"11","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen DJ, Sauerbier A, Leta V, Rodriguez-Blazquez C, Falup-Pecurariu C, Rodriguez-Violante M, Rizos A, Tsuboi Y, Metta V, Bhidayasiri R, Bhattacharya K, Borgohain R, Prashanth LK, Rosales R, Lewis S, Fung V, Behari M, Goyal V, Kishore A, Lloret SP, Martinez-Martin P, Chaudhuri KR (2021b) Cross-sectional analysis of the Parkinson\u2019s disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. Sci Rep 11(1):9611. https:\/\/doi.org\/10.1038\/s41598-021-88651-4","journal-title":"Sci Rep"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-023-02603-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02603-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T15:04:04Z","timestamp":1687791844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-023-02603-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2603"],"URL":"https:\/\/doi.org\/10.1007\/s00702-023-02603-y","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"15 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VL has received travel grants and honoraria for speaker-related activity from Bial, outside the submitted work. DvW has received travel grants and speaker fees from Bial, outside the submitted work. AR has received salary support from National institute of Health Research (NIHR) Clinical Research Network (CRN) South London, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK; International Parkinson and Movement Disorder Society (MDS) 555 East Wells Street, Suite 1100, Milwaukee, WI 53202-3823 USA, outside the submitted work. KRC reports advisory board for AbbVie, UCB, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, Scion, Britannia; honoraria for lectures from AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim; grants (Investigator Initiated) from Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial; academic grants from EU, IMI EU, Horizon 2020, Parkinson\u2019s UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, Wellcome Trust, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}